Opinion

Video

Anticipating Key Studies and Pipeline Treatments in mCRC Landscape

Author(s):

Aparna R. Parikh, MD,Marwan G. Fakih, MD

The experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Dr Fakih on the Future of Botensilimab and Balstilimab–Based Therapies in MSS mCRC
Alberto Chiappori, MD
Dr Fakih on the FDA Approval of Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC
Kanwal P.S. Raghav, MBBS, MD
4 experts are featured in this series.
Richard T. Lee, MD, Cherng Family Director’s Chair, Center for Integrative Oncology, medical director, clinical professor, Supportive & Integrative Medicine, Department of Supportive Care Medicine, City of Hope
E. Gabriela Chiorean, MD, FASCO, clinical director, GI Medical Oncology Program, professor, Clinical Research Division, and affiliate investigator, Translational Science and Therapeutics Division Fred Hutchinson Cancer Center; professor, medicine, University of Washington; director, Clinical Research GI Oncology Program, University of Washington/Fred Hutch
Daneng Li, MD, associate professor, Department of Medical Oncology & Therapeutics Research, and co-director, Neuroendocrine Tumor Program, City of Hope
Related Content
Ajay Goel, PhD, AGAF, professor, chair, Department of Molecular Diagnostics and Experimental Therapeutics at City of Hope in Duarte, California
March 19th 2025

CA19-9 Plus Liquid Biopsy Represents Diagnostic Biomarker of Interest for Early-Stage Pancreatic Cancer Detection

Marwan G. Fakih, MD
March 3rd 2025

FDA Approval Insights: Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC: With Marwan Fakih, MD

The top 5 OncLive videos of the week cover insights in colorectal cancer, myeloma, HER2+ breast cancer, and KRAS G12X+ pancreatic ductal adenocarcinoma.
March 16th 2025

Five Under 5: Top Oncology Videos for the Week of 3/9

Alexey Danilov, MD, PhD, Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director, Early Phase Therapeutics Program, the Systems Clinical Trials Office, co-director, Toni Stephenson Lymphoma Center, professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; Susan M. O'Brien, MD, associate director, Clinical Science, Chao Family Comprehensive Cancer Center, medical director, Sue & Ralph Stern Center for Clinical Trials & Research, professor, medicine, Division of Hematology/Oncology, University of California Irvine School of Medicine
December 31st 2024

Explore the Evolving Role of BTK Inhibitors in CLL: With Alexey Danilov, MD, PhD; and Susan M. O'Brien, MD

Abemaciclib in High-Risk Early Breast Cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
March 8th 2025

Abemaciclib Delivers Consistent Benefit in High-Risk, Early Breast Cancer Regardless of Dose Reductions

Sewit Teckie, MD, system chief, Radiation Oncology, director, Head and Neck Radiation Oncology, NYC Health + Hospitals
March 6th 2025

Cell-Free DNA Blood-Based Assay Is Not Superior to Colonoscopy in Colorectal Cancer